Mark Voellinger, MD
Gastroenterology · Wheeling, WVNPI 1619170693
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,350 of the $45,236 with a category attached, or 64.9%. AbbVie accounts for 77.2% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $13,718, 6.9 times the $2,001 reported in 2019. Among gastroenterology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,068 payments — averaging $42.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$35K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Braintree Laboratories, Inc.$999
- Pfizer$834
- Ironwood Pharmaceuticals, Inc$660
- Sanofi$631
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$29,35065%
- Travel & lodging$1370%
- Food & beverage$15,17234%
- Education$70%
- Gifts$5701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 321 | $34,915 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 347 | $3,400 |
| Braintree Laboratories, Inc. | 39 | $999 |
| Pfizer | 61 | $834 |
| Ironwood Pharmaceuticals, Inc | 41 | $660 |
| Sanofi | 31 | $631 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $611 |
| Madrigal Pharmaceuticals | 40 | $531 |
| Bristol Myers Squibb | 31 | $356 |
| Johnson & Johnson | 15 | $267 |
| Phathom Pharmaceuticals, Inc. | 18 | $244 |
| Ardelyx, Inc. | 12 | $232 |
| Gilead | 12 | $211 |
| QOL Medical, LLC | 13 | $209 |
| Boston Scientific | 1 | $145 |
| Abbott | 2 | $142 |
| Merck | 7 | $123 |
| Alfasigma USA, Inc. | 6 | $80 |
| Fresenius Kabi USA, LLC | 4 | $70 |
| Edwards Lifesciences | 1 | $69 |
| UCB, Inc. | 3 | $58 |
| AstraZeneca | 1 | $54 |
| Novartis | 1 | $50 |
| Amgen | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| CSL Behring | 1 | $38 |
| Bayer | 1 | $37 |
| Redhill Biopharma Inc. | 2 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Shionogi Inc | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $22 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$14,853
- Rinvoq$12,576
- WATCHMAN Access System$145
- FREESTYLE LIBRE 3$126
How this compares
$45,236 in reported general payments places this provider in the 90th percentile of 72 gastroenterology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 17 | $240,509 |
| Humira(Cf) PenAdalimumab | 20 | $137,885 |
| XifaxanRifaximin | 39 | $125,127 |
| CreonLipase/Protease/Amylase | 16 | $121,035 |
| OcalivaObeticholic Acid | 12 | $111,606 |
| ZeposiaOzanimod Hydrochloride | 12 | $108,808 |
| LinzessLinaclotide | 103 | $108,281 |
| IbsrelaTenapanor Hcl | 39 | $71,147 |
| Mesalamine | 40 | $24,998 |
| TrulancePlecanatide | 21 | $18,547 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 76 | $12,950 |
| Balsalazide Disodium | 69 | $10,011 |
| Dexlansoprazole DrDexlansoprazole | 32 | $8,247 |
| Budesonide DrBudesonide | 61 | $6,138 |
| Pantoprazole Sodium | 343 | $5,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $209 | $240,50917 claims |
| AbbVieCreon, Linzess | $34,915 | $229,316119 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $3,400 | $143,67460 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $17 | $111,60612 claims |
| Ardelyx, Inc.Ibsrela | $232 | $71,14739 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $15 | $12,95076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 gastroenterology providers in West Virginia.
Other gastroenterology in Wheeling
- John DorseyWheeling$4K
- Scott NaumWheeling$2K
- Jennifer VeverkaMorgantown$283K
- Shailendra SinghMorgantown$187K
- Mohamad HaffarSouth Charleston$118K
- Shyam ThakkarMorgantown$113K
- Hazem Al-AshhabParkersburg$93K
- John NasrMorgantown$30K
- Wesam FrandahHuntington$28K
- Matthew KrafftMorgantown$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.